Welcome to our dedicated page for Aurinia Pharmace SEC filings (Ticker: AUPH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Aurinia Pharmaceuticals Inc.'s SEC filings document the formal reporting record for a Canada-incorporated biopharmaceutical company commercializing LUPKYNIS and developing autoimmune-disease therapies. 8-K filings furnish operating and financial results, product revenue, license, collaboration and royalty revenue, research and development spending, guidance-related exhibits and other material-event disclosures.
The filings also cover proxy governance, executive appointments and compensatory arrangements, shareholder voting matters, capital-structure disclosures, share repurchase activity and material agreements. Recent transaction records include completed acquisition activity, tender-offer and merger mechanics, and contingent value right terms.
Aurinia Pharmaceuticals Inc.'s EVP and General Counsel, Stephen P. Robertson, reported a Form 4 transaction involving company common stock. On February 20, 2026, 34,638 shares of common stock at $14.40 per share were disposed of to satisfy tax withholding obligations tied to vesting restricted stock units, rather than through an open-market sale. After this tax-withholding disposition, Robertson’s directly held ownership stood at 483,296 common shares.
Aurinia Pharmaceuticals senior vice president and chief medical officer Greg Keenan reported a routine share withholding tied to equity compensation. On 02/02/2026, 11,552 shares of common stock were withheld at $14.53 per share to satisfy tax obligations when restricted stock units vested.
After this tax-related withholding, Keenan beneficially owns 121,932 shares of Aurinia common stock, held directly. The filing reflects an administrative adjustment rather than an open-market purchase or sale, and confirms his ongoing equity stake in the company.
Aurinia Pharmaceuticals Inc. (AUPH) filed a Form 4 reporting a tax-related share withholding by a director. On 11/21/2025, a director had 2,716 common shares withheld at a price of $15.68 per share to cover tax obligations when restricted stock units vested. This was recorded as a disposition of shares for tax purposes, not an open-market sale. After this transaction, the director beneficially owns 22,775 common shares, held directly.
The filing clarifies that the reported transaction represents shares withheld to satisfy tax withholding obligations upon RSU vesting, which is a common administrative equity compensation event for insiders.
Aurinia Pharmaceuticals Inc. (AUPH) reported an insider equity transaction on a Form 4 involving one director. On 11/21/2025, the director had 6,039 common shares withheld at a price of $15.68 per share to cover tax withholding obligations tied to the vesting of restricted stock units. After this tax-related withholding, the director directly beneficially owned 14,592 common shares of Aurinia. This event reflects routine equity compensation and tax management rather than an open-market purchase or sale.
Aurinia Pharmaceuticals Inc. (AUPH) furnished an 8‑K on November 4, 2025 announcing it issued a press release for its financial results for the quarter ended September 30, 2025. The press release is provided as Exhibit 99.1, with a Third Quarter 2025 Update as Exhibit 99.2.
The information was furnished under Item 2.02 and is not deemed “filed” for purposes of Section 18 of the Exchange Act, nor incorporated by reference except as specifically stated. The report was signed by Chief Financial Officer Joseph Miller.
Aurinia Pharmaceuticals (AUPH) reported stronger Q3 2025 results, led by continued LUPKYNIS growth and lower operating costs. Total revenue was $73.5 million, up from $67.8 million a year ago, with net product sales of $70.6 million. Net income rose to $31.6 million from $14.4 million as SG&A spending declined following 2024 restructuring actions. Gross margin was 89% for the quarter.
Year to date, revenue reached $205.9 million and net income was $76.4 million. Operating cash flow for the nine months was $90.0 million. Cash, cash equivalents, restricted cash and investments were $351.8 million as of September 30, 2025. The company repurchased 12.2 million common shares year to date under its authorized program. Common shares outstanding were 131,840,559 as of November 3, 2025.
This Amendment No. 16 to the Schedule 13D reports the holdings and recent transactions by ILJIN-related reporting persons in Aurinia Pharmaceuticals Inc.'s common shares. Chin Kyu Huh beneficially owns 6,535,141 shares, equal to 5.0% of the outstanding class, and certain ILJIN entities report shared voting and dispositive power over 5,411,533 shares (4.1%). The filing states small purchases by family members and material secondary-market sales by ILJIN SNT and a family member, with per-share prices disclosed.
The filing also states the Reporting Persons may be deemed a group for Section 13(d)(3) purposes while disclaiming certain beneficial ownerships among family members and entities. All percentage calculations are based on 131,629,546 shares outstanding as reported by the issuer.
Aurinia Pharmaceuticals Inc. (AUPH) – Form 4 insider buying
Director Kevin Tang, through Tang Capital Partners LP and Tang Capital Partners International LP, purchased a total of 1,300,000 common shares in three open-market transactions dated 1-5 Aug 2025 (transaction code P). Weighted-average purchase prices were:
- 1,000,000 sh @ $10.12 (range $9.23-$10.50)
- 100,000 sh @ $11.34 (range $11.11-$11.48)
- 200,000 sh @ $11.68 (range $11.49-$11.80)